Valuation: Opus Genetics, Inc.

Market Cap 323M 280M 262M 239M 450M 30.79B 457M 3.07B 1.2B 15.41B 1.21B 1.19B 51.41B P/E 2026 *
-3.9x
P/E 2027 * -5.5x
Enterprise Value 323M 280M 262M 239M 450M 30.79B 457M 3.07B 1.2B 15.41B 1.21B 1.19B 51.41B EV / Sales 2026 *
23.6x
EV / Sales 2027 * 22.4x
Free-Float
89.06%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Opus Genetics, Inc.

1 day+6.01%
1 week+4.58%
Current month+4.58%
1 month-1.02%
3 months-24.22%
6 months+17.93%
Current year+93.03%
1 week 3.52
Extreme 3.525
3.96
1 month 2.82
Extreme 2.82
3.96
Current year 1.88
Extreme 1.88
5.81
1 year 1.04
Extreme 1.04
5.81
3 years 0.65
Extreme 0.65
5.81
5 years 0.65
Extreme 0.65
6.6
10 years 0.65
Extreme 0.65
13.81
Manager TitleAgeSince
Chief Executive Officer 42 01/11/2023
Director of Finance/CFO 52 02/09/2025
President 60 22/10/2024
Director TitleAgeSince
Director/Board Member 77 01/11/2020
Chairman 56 01/12/2019
Director/Board Member 59 01/11/2020
Date Insider Type Main position Quantity % Market Cap.
7/23/26 A Sell

Chief Financial Officer

-7,783 0.0094%
7/23/26 A Sell

Chairperson

-7,429 0.0090%
7/23/26 A Sell

Chief Executive Officer

-9,475 0.0115%
Change 5-day change 1-year change 3-year change Capi.($)
+6.01%+4.58%+266.04%-8.06% 323M
-1.37%+8.90%+91.28%+130.00% 1,083B
-0.77%+1.91%+49.46%+49.44% 626B
+0.85%+2.58%+25.90%+64.34% 442B
-1.56%-0.52%+47.24%+36.98% 363B
-1.72%-0.48%+28.71%+36.23% 295B
-1.06%-2.81%+5.52%+5.25% 248B
-0.70%+6.23%+45.32%+57.82% 224B
-3.17%+1.12%-7.15%-51.95% 210B
+2.04%+0.38%+12.70%+69.71% 168B
Average -0.15%+1,496.94%+56.50%+38.98% 365.94B
Weighted average by Cap. -0.93%+1,332.50%+48.95%+65.41%

Financials

2026 *2027 *
Net sales 13.65M 11.83M 11.08M 10.11M 19.02M 1.3B 19.34M 130M 50.88M 652M 51.26M 50.14M 2.17B 14.44M 12.52M 11.72M 10.69M 20.12M 1.38B 20.46M 137M 53.83M 689M 54.23M 53.05M 2.3B
Net income -93.25M -80.81M -75.65M -69.03M -130M -8.89B -132M -887M -348M -4.45B -350M -343M -14.85B -67.83M -58.78M -55.03M -50.21M -94.49M -6.47B -96.08M -645M -253M -3.24B -255M -249M -10.8B
Net Debt - -
Logo Opus Genetics, Inc.
Opus Genetics, Inc. is a clinical-stage ophthalmic biotechnology company. The Company is engaged in developing gene therapies for the treatment of inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. The Company’s pipeline includes adeno-associated virus (AAV)-based investigational gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. Its pipeline also includes OPGx-BEST1 investigational gene therapy, designed to address mutations in the BEST1 gene, which is associated with retinal degeneration. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist being investigated to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 being investigated to slow the progression of non-proliferative diabetic retinopathy.
Employees
28
Date Price Change Volume
11/08/26 $3.880 +6.01% 538,402
10/08/26 $3.660 0.00% 608,169
07/08/26 $3.660 -1.61% 915,167
06/08/26 $3.720 -1.59% 681,111
05/08/26 $3.780 +1.89% 872,254
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
19
Last Close Price
3.880USD
Average target price
10.61USD
Spread / Average Target
+173.48%

Quarterly revenue - Rate of surprise